Anumana, an artificial intelligence (AI)-based health technology firm, has partnered with AliveCor to advance AI-based algorithms for the early detection of cardiac diseases.
Under the collaboration, both companies will develop Anumana’s advanced AI algorithms for early cardiac disease detection on AliveCor’s Kardia electrocardiogram (ECG) devices.
The partnership begins with the US Food and Drug Administration (FDA)-cleared ECG-AI LEF algorithm, designed for early cardiac disease detection.
AliveCor chief business officer Sanjay Voleti said: “AliveCor is already at the forefront of AI in cardiology, transforming the industry with clinically validated solutions that disrupt traditional care pathways to create a more connected, holistic cardiac health ecosystem, like the recently FDA-cleared Kardia 12L ECG System.
“This collaboration with Anumana will further strengthen our leadership in AI by expanding our solutions’ ability to facilitate more personalised and timely care across diverse healthcare settings.”
Anumana’s ECG-AI platform offers algorithms to detect hard-to-identify cardiovascular diseases without expensive, invasive or difficult-to-access clinical tests.
Its algorithms will be integrated into the Kardia 12L ECG System, which secured FDA clearance in June last year.
The partnership with AliveCor aims to identify cardiac conditions earlier, helping patients access clinical care sooner.
The ECG-AI LEF algorithm, cleared by the FDA in 2023, detects LEF using routine 12-lead ECG data.
LEF is a commonly underdiagnosed indicator of heart failure. It was recently included in the CMS 2025 Hospital Outpatient Prospective Payment System final rule.
Anumana chief business officer David McMullin said: “Together with AliveCor, we are reshaping the future of cardiac care by unlocking new possibilities for early detection and intervention.
“This collaboration demonstrates Anumana’s commitment to harnessing the potential of AI to expand the utility of ECG technology, making traditional diagnostic tools more powerful for patients and clinicians.”
In June 2024, Anumana announced a partnership with digital health company InfoBionic.Ai to advance AI-based remote cardiac telemetry technology for the early detection of cardiac diseases.
